Genferon light suppositories for children 125. Genferon antiviral suppositories for children
The page contains instructions for use Genferon. It is available in various dosage forms of the drug (suppositories 125,000, 500,000, 1,000,000 and Light spray), and also has a number of analogues. This abstract has been verified by experts. Leave your feedback on the use of Genferon, which will help other site visitors. The drug is used for various diseases (herpes, chlamydia, trichomoniasis). The product has a number of side effects and interactions with other substances. Doses of the drug differ for adults and children. There are restrictions on the use of the medicine during pregnancy and breastfeeding. Treatment with Genferon can only be prescribed by a qualified doctor. The duration of therapy may vary and depends on the specific disease.
Instructions for use and dosage regimen
For infectious and inflammatory diseases of the urogenital tract in women, the drug is prescribed intravaginally, 1 suppository (250 thousand or 500 thousand IU, depending on the severity of the disease) 2 times a day for 10 days. For chronic diseases, the drug is prescribed 3 times a week (every other day), 1 suppository for 1-3 months.
For infectious and inflammatory diseases of the urogenital tract in men, the drug is prescribed rectally, 1 suppository (500 thousand-1 million IU, depending on the severity of the disease) 2 times a day for 10 days.
At the first signs of the disease, Genferon Light spray is administered intranasally for 5 days, one dose (one press on the dispenser) into each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alfa-2b, the daily dose should not exceed 500,000 IU).
In case of contact with a patient with acute respiratory viral infection and/or hypothermia, the drug is administered according to the indicated regimen 2 times a day for 5-7 days. If necessary, preventive courses are repeated.
Instructions for use of the spray
1. Remove the protective cap.
2. Before using for the first time, press the dispenser several times until a thin stream appears.
3. When using, keep the bottle in an upright position.
4. Inject the drug by pressing the dispenser once into each nasal passage in turn.
5. After use, close the dispenser with the protective cap.
Release forms
Suppositories for vaginal or rectal use 250,000 ME, 500,000 ME, 1,000,000 ME.
Genferon Light suppositories vaginal or rectal 125,000 ME.
Spray for nasal use Genferon Light dosed 50 thousand IU + 1 mg/dose.
Genferon- a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic immunomodulatory effects.
Interferon alpha-2 has antiviral, antimicrobial and immunomodulatory effects. Under the influence of interferon alpha-2, the activity of natural killer cells, T-helper cells, phagocytes, as well as the intensity of differentiation of B-lymphocytes increases. Activation of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of primary pathological foci and restoration of the production of secretory immunoglobulin A.
Taurine has membrane and hepatoprotective, antioxidant and anti-inflammatory properties, enhances tissue regeneration.
Benzocaine is a local anesthetic. Reduces the permeability of cell membranes to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers.
Pharmacokinetics
When administered vaginally or rectally, interferon alfa-2 is absorbed through the mucous membrane, enters the surrounding tissues, and enters the lymphatic system, providing a systemic effect. Also, due to partial fixation on the cells of the mucous membrane, it has a local effect.
A decrease in the level of serum interferon 12 hours after administration of the drug necessitates its repeated administration.
Indications
As part of complex therapy for infectious and inflammatory diseases of the urogenital tract:
- genital herpes;
- chlamydia;
- ureaplasmosis;
- mycoplasmosis;
- recurrent vaginal candidiasis;
- gardnerellosis;
- trichomoniasis;
- human papillomavirus infections;
- bacterial vaginosis;
- cervical erosion;
- cervicitis;
- vulvovaginitis;
- bartholinitis;
- adnexitis;
- prostatitis;
- urethritis;
- balanitis;
- balanoposthitis.
Contraindications
- hypersensitivity to the components of the drug.
Special instructions
The drug should be prescribed with caution to patients with allergic and autoimmune diseases in the acute stage.
Side effect
- skin rash, itching (these phenomena are reversible and disappear 72 hours after reducing the dose or stopping the drug);
- headache;
- leukopenia, thrombocytopenia;
- increased body temperature;
- increased sweating;
- fatigue;
- myalgia;
- loss of appetite;
- arthralgia (joint pain).
Drug interactions
When used together with antibiotics and other antimicrobial drugs used to treat urogenital infections, the effectiveness of Genferon increases.
When used simultaneously with vitamins E and C, the effect of interferon is enhanced.
When used together with nonsteroidal anti-inflammatory drugs and anticholinesterase drugs, the effect of benzocaine is potentiated.
When used together, the antibacterial activity of sulfonamides decreases (due to the action of benzocaine).
Analogues of the drug Genferon
The drug Genferon has no structural analogues for the active substance. However, there is a whole class of similar drugs that have a different chemical structure of their composition:
- Altevir;
- Alfarona;
- Alfaferon;
- Wellferon;
- Grippferon;
- Interferal;
- Interferon alpha-2 human recombinant;
- Intron A;
- Inferon;
- Laifferon;
- Lokferon;
- Oftalmoferon;
- Realdiron;
- Reaferon-EC.
Use during pregnancy and breastfeeding
If it is necessary to use the drug in the 2nd and 3rd trimesters of pregnancy, the expected benefit to the mother should be weighed against the potential risk to the fetus.
Compound
1 suppository for dosages of 125,000 ME + 5 mg, 250,000 ME + 5 mg, respectively, contains:
active substances: interferon alpha-2b human recombinant (rhIFN-α) -125,000 IU, 250,000 IU; taurine - 0.005 g;
excipients: “hard fat”, dextran 60000, macrogol 1500, polysorbate 80, T2 emulsifier, sodium hydrogen citrate, citric acid monohydrate, purified water.
Description
White or white with a yellowish tint, cylindrical suppositories with a pointed end are uniform in longitudinal section. An air rod or funnel-shaped depression is allowed on the cut.
Pharmacological properties
Pharmacodynamics
Immunobiological properties
Recombinant interferon alpha-2b, which is the active component of Genferon® Light suppositories, has antiviral, immunomodulatory, indirect antibacterial and antiproliferative properties. The antiviral effect of interferon alpha-2b is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by an increase in cell-mediated reactions of the immune system. Interferon increases the cytotoxicity of T-lymphocytes, natural killer cells, the phagocytic activity of macrophages, promotes the differentiation of T-helper cells, and protects T-cells from apoptosis. The immunomodulatory effect of interferon is also due to its influence on the production of a number of cytokines (interleukins, interferon gamma). All of these effects of interferon may mediate its therapeutic activity. The immunogenicity of recombinant interferon alpha-2b in Genferon® Light suppositories has not been studied.
Taurine is a natural metabolic product of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells.
Pharmacokinetics
When used intravaginally, due to the high concentration at the site of infection, a local antiviral and antibacterial effect is achieved, while there is no systemic absorption.
A special study of the pharmacokinetics of interferon alpha-2b, which is part of the Genferon® Light suppositories, with rectal and vaginal administration was not carried out. Based on the results of our own studies of the pharmacokinetics of interferon alpha-2b, which is included in the Genferon® suppositories (interferon alpha-2b + taurine + benzocaine), with rectal administration did not reveal an increase in the level of serum interferon, nor was there a systemic effect on the concentration of neopterin, individual cytokines, 2'5'-oligoadenylate synthetase, levels of basic immunoglobulins, which may be due to the insufficient sensitivity of the test system used, as well as the rapid binding of interferon to cellular receptors and the removal of free cytokine from the bloodstream. The effect is likely due to a series of paracrine reactions, initially directly on immunocompetent cells at the injection site, followed by activation of antigen-presenting cells and T-lymphocytes. There are separate literature data describing the systemic absorption of interferon during rectal administration of suppositories containing interferon alfa-2b. A special study of the pharmacokinetics of taurine, which is part of the Genferon® Light suppositories, with rectal and vaginal administration has not been conducted.
Indications for use
As a component of complex therapy in adults and children, including newborns, for the following diseases:
Adults:
as part of complex therapy for urogenital infections caused by Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis, herpes simplex virus (HSV type 1 and type 2) or mixed infections in women, including pregnant women in the 2-3 trimester.
Children:
- ARVI;
- chicken pox (no later than 24 hours from the appearance of the first elements of a vesicular rash);
- acute intestinal infections (with the duration of symptoms of the disease no more than 48 hours);
- vulvovaginitis in girls over 13 years of age caused by Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis, herpes simplex virus (HSV type 1 and type 2), CMV or mixed infections.
Directions for use and doses
The drug can be used both vaginally and rectally. The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon® Light is used at a dose of 250,000 IU interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU interferon alfa-2b per suppository.
Recommended doses and treatment regimens:
Acute respiratory viral infections in children:
1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
Chicken pox in children:
1 suppository rectally 2 times a day with a 12-hour
at intervals of 5 days against the background of standard therapy.
Acute intestinal infections in children
: 1 suppository rectally 2 times a day with
12-hour intervals for 5 days against the background of standard therapy.
Vulvovaginitis in girls over 13 years of age
: 1 suppository rectally 2 times a day
day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in pregnant women
: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in women
: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Side effect
The drug is well tolerated by patients. Very rare (frequency less than 1 in 10,000 cases): there are isolated reports of cases of allergic reactions. These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor.
To date, no severe or life-threatening side effects have been observed.
Contraindications
Individual intolerance to interferon and other substances included in the drug;
- allergic and autoimmune diseases in the acute stage;
- severe broncho-obstructive syndrome, requiring a course of glucocorticosteroids;
- chronic diseases in the stage of decompensation, as well as congenital malformations, metabolic diseases, hereditary diseases;
- diseases of the thyroid gland;
- severe impairment of kidney and liver function;
- severe cardiovascular diseases;
- epilepsy and other diseases of the central nervous system;
- HIV infection, congenital immunodeficiency;
- inhibition of the myeloid lineage of hematopoiesis: neutropenia, thrombocytopenia;
- I trimester of pregnancy due to lack of data.
Precautions
When treating primary and recurrent herpetic infections, it is not recommended to use the drug Genferon® Light vaginal and rectal suppositories in the following cases:
- for common, atypical and generalized forms of herpetic infection;
- in the presence of clinical signs of atopic dermatitis, eczema, seborrheic dermatitis, benign familial pemphigus Gougerot-Hailey;
- for skin tumors;
- for mental disorders requiring treatment with antidepressants, tranquilizers or hospitalization;
- with neutropenia less than 1.5 * 10 9 /l;
- with thrombocytopenia less than 90,000 cells/µl;
- for diseases associated with dysfunction of the immune system.
Use during pregnancy and lactation
Clinical studies have proven the effectiveness and safety of using Genferon® Light in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.
Genferon Light (suppositories, spray) – instructions for use, analogues, price and reviews
Thank you
The site provides reference information for informational purposes only. Diagnosis and treatment of diseases must be carried out under the supervision of a specialist. All drugs have contraindications. Consultation with a specialist is required!
Medicine Genferon Light is an immunomodulator with antiviral activity, which is used to treat inflammatory pathologies of the urinary and reproductive systems in adult men and women, as well as acute respiratory diseases or infections in children and adults.Genferon Light effectively fights a wide range of pathogenic microorganisms:
Genferon Light activates and normalizes the properties of the human immune system, which begins to more effectively fight any pathogenic microbes and tumor cells, not only eliminating the source of infection, but also preventing infection by other types of microorganisms.
Release forms
Today, the drug Genferon Light is available in two main dosage forms:1. Suppositories in dosages of 125,000 IU and 250,000 IU.
2. Nasal spray 50,000 IU.
Genferon Light suppositories are inserted into the vagina or rectum. Available in two dosages - 125,000 IU and 250,000 IU in one suppository, which are often briefly designated: Genferon 125 or Genferon 250. Spray for intranasal administration contains 50,000 IU in one dose.
Description
Suppositories Genferon Light Both dosages are cylindrical in shape, pointed at one end. It has a white or yellow-white color on the outside, the internal contents look uniform when cut. In some candles, the cut may show oblong air rods or a funnel-shaped recess. Genferon Light suppositories of both dosages (125,000 IU and 250,000 IU) are available in packages of 5 or 10 pieces.Spray Genferon Light It is a transparent liquid with a yellowish tint or completely colorless. The liquid is completely homogeneous and should not contain any inclusions or suspended particles. The spray is available in bottles with a nozzle that allows you to dispense liquid. One dose contains 50,000 IU of active substance, and the entire bottle is designed for 100 doses.
Compound
All pharmaceutical forms of the drug Genferon Light contain interferon alpha 2b and taurine as active substances. Moreover, Genferon Light 125,000 contains interferon alpha 2b in a dose of 125,000 IU, and taurine in the amount of 0.005 g. Genferon Light 250,000 contains interferon alpha 2b in a dose of 250,000 IU, and taurine in the amount of 0.005 g. One dose of Genferon Light spray contains interferon alpha 2b at a dose of 50,000 IU, and taurine - 0.001 g. Suppositories contain the following components as excipients:
- hard fat;
- dextran 60,000;
- polysorbate 80;
- emulsifier T2;
- sodium hydrogen citrate;
- citric acid;
- water for injections.
- sodium EDTA;
- glycerol;
- dextran 40000;
- polysorbate 80;
- sodium chloride;
- potassium chloride;
- potassium dihydrogen phosphate;
- peppermint oil;
- methyl parahydroxybenzoate;
- water for injections.
Absorption, distribution and excretion from the body
Suppositories. Rectal administration ensures absorption of 80% of the drug, due to which Genferon Light has both local and systemic effects. Complete absorption of the drug and maximum concentration in the blood is achieved 5 hours after rectal administration of the suppository. Half of the administered dose is eliminated within 12 hours. The components of the drug are converted into metabolites in the kidneys and are excreted from the body in the urine.The introduction of suppositories into the vagina provides a local effect, since a small amount of the active substance is absorbed into the blood. This retention of the components of the drug is ensured by the properties of the vaginal mucosa, which fixes interferon and taurine on the surface of its cells.
Spray. When the drug is administered into the nose, the absorption of Genferon Light is insignificant, so the systemic effect is weakly expressed. Intranasal use of the drug provides a strong local effect, since the components of the drug are fixed on the mucous membrane of the nasal cavity. The retention of interferon and taurine on the nasal mucosa is ensured by a complex of 25 proteins.
Therapeutic effect (properties)
The therapeutic effects of the drug Genferon Light are due to two substances - interferon alpha 2b and taurine. Interferon alpha 2b has the following properties:- antiviral effect;
- antimicrobial effect (bacteria, fungi, etc.);
- antiproliferative effect (stops the proliferation of microbes and tumor cells);
- immunomodulatory effect (normalization of immune system functions);
- immunostimulating effect (increasing the efficiency of the immune system);
- anti-inflammatory effect.
Interferon is able to directly influence intracellular organisms (viruses and chlamydia), stopping their reproduction. The antiviral effect is also explained by the activation of the immune response, which is able to effectively remove pathogenic microorganisms and body cells infected by them. In this situation, healthy cells create a good immune defense against infected structures, stopping further penetration of pathogenic particles into uninfected cells. Interferon is able to bind to the cell membrane and change its properties in such a way that viruses and bacteria cannot penetrate inside. And this, in turn, leads to the impossibility of reproduction. In addition, interferon interacts with the cell nucleus and reduces the production of proteins for the virus, which also leads to a stop in reproduction. Thus, stopping the proliferation of viral and bacterial cells makes it possible to delimit the pathogenic focus, after which immunocompetent cells are effectively destroyed and removed from the body.
Antiproliferative effect
Interferon is capable of changing the properties and structure of cell membranes, as well as regulating the processes of cell reproduction and maturation. Genferon Light stops the growth of tumor cells and stops the proliferation of virus-infected structures. Genferon Light suppresses the reproduction of infected cells at different rates, depending on the type of pathogenic microorganism.
Immunomodulatory and immunostimulating effects
Interferon enhances the activity of macrophages and natural killer cells (NK cells), which capture and destroy pathogenic microorganisms, infected cells and viral particles. Genferon Light increases the efficiency of phagocytosis, accelerates the process of recognition of microbes and improves the processes of cooperation between immune cells.
Interferon stimulates the production of antibodies by B lymphocytes (including immunoglobulin A), activates leukocytes, which are able to quickly localize the source of infection and eliminate it. Immunoglobulin A creates immune protection on the mucous membranes, preventing the penetration of pathogenic microorganisms into the body.
Contraindications
Suppositories Genferon Light are absolutely contraindicated in the following cases:- sensitivity, intolerance or allergy to any components of the drug;
- pregnancy up to 12 weeks;
- epilepsy or other seizure conditions;
- severe heart disease.
Instructions for use
Suppositories of both dosages can be used rectally and vaginally. The choice of method of administration and dosage of suppositories depends on the location of the pathology, the severity of its course, the characteristics of the clinic, the age and gender of the patient.Treatment regimens with Genferon Light, depending on age and nature of the disease, are shown in the table:
| Pathology | Patient age | Treatment regimen |
| Acute infections urinary system | Children | 1 suppository in the anus twice a day for 10 days |
| Pregnant women | 1 suppository in the vagina twice a day for 10 days | |
| Inflammation of the urinary system | Adult women and men | 1 suppository 250,000 IU vaginally and rectally twice a day for 10 days. Treatment of long-term chronic pathology after this course is continued for 1-3 months, 1 suppository per day every other day |
| Acute viral pathologies (including ARVI) | Children | 1 suppository in the anus twice a day for 5 days. If symptoms partially remain, you can repeat the course of treatment after 5 days |
| Chronic viral pathology | Children | 1 suppository rectally twice a day for 10 days. Then for 1-3 months, 1 suppository in the evening every other day |
An overdose of Genferon Light is impossible. However, if a large number of suppositories are administered at the same time, you should stop using the drug for a day (24 hours), and then continue taking it according to the regimen prescribed by your doctor.
Genferon Light is highly effective as part of complex therapy for diseases of an infectious and inflammatory nature. The following drugs mutually enhance each other's effects when used together with Genferon Light:
1.
Antibacterial agents (antibiotics, sulfa drugs, antiseptics);
2.
Antifungal drugs;
3.
Antiviral drugs.
Genferon Light does not affect the activity of the nervous system, therefore, while taking the drug, you can do work that requires attention.
If the temperature rises in response to the introduction of the Genferon Light suppository, it is allowed to take paracetamol in a dose of 500-1000 mg for an adult, and 250 mg for a child.
Instructions for use in children
The drug Genferon Light is not a specialized medicine for children, but can be used to treat a child. Children under 7 years of age can use Genferon Light suppositories at a dosage of 125,000 IU, which is conventionally called children's dosage. Children over 7 years of age can use 250,000 IU suppositories if indicated, or if the disease is severe and protracted.Newborns and premature babies (8 months old) can use Genferon Light 125,000 IU twice a day for 5 days. Premature babies born before 8 months receive Genferon Light 1 suppository 125,000 IU three times a day (every 8 hours), for 5 days. Such courses of treatment are repeated if necessary (pneumonia, herpetic infection, sepsis, meningitis, mycoplasmosis, cytomegalovirus infection).
For children over 7 years of age, the following treatment regimen for various pathologies is recommended:
1.
Acute infections of the urinary system: 1 suppository twice a day for 10 days (rectal administration).
2.
Acute viral inflammations of different localization: 1 suppository twice a day for 5 days (rectal administration). If the clinical symptoms have not disappeared completely, then repeat the course of treatment after a 5-day break.
3.
Chronic viral inflammations of different localization: 1 suppository twice a day for 10 days (rectal administration). After this course, continue maintenance therapy - 1 suppository in the evening, for 1-3 months; enter every other day.
Side effects
Genferon Light suppositories rarely cause side effects. This is mainly due to the high daily dose of the drug. Most often, allergic manifestations develop - itching, burning sensation in the vagina or rectum. These unpleasant symptoms disappear without intervention three days after stopping the drug. In rare cases, the following adverse reactions may develop:
- increase in temperature;
- severe heart pathology;
Instructions for use
The spray is administered into both nasal passages using a short press, which corresponds to one dose. The medicine is used according to the following scheme:1. Remove the cap.
2. Release a short test stream by pressing the dispenser several times.
3. Insert the dispenser into the nasal passage and place the bottle in a vertical position.
4. Briefly press the dispenser and inhale the spray deeply.
5. Close the cap.
The use of Genferon Light spray begins at the first signs of the development of an acute respiratory viral disease or influenza in children and adults. The spray is administered into both nasal passages, one dose three times a day, for 5 days. Remember that the maximum allowed number of doses per day is 10 (ten clicks on the dispenser).
There is another scheme for using Genferon Light spray for the treatment of acute viral diseases: when the first signs of pathology appear, within 3-4 hours, administer one dose of the spray into each nasal passage, every 20 minutes. After this, one dose should be administered into the nasal passages 4-5 times a day, for 3-4 days.
In order to prevent ARVI and influenza upon contact with sick people, or after suffering from hypothermia, Genferon Light spray is used for 5-7 days, twice a day, one dose (one press on the dispenser) in each nasal passage. The duration of prophylactic use of the spray can be increased until the danger of infection ends. Courses for the prevention of viral diseases can be carried out as necessary.
To prevent infection from each other, you should use an individual bottle of spray for each person.
The possibility of overdose with this spray has not been identified.
Genferon Light spray does not interact with other medications.
Side effects
To date, no side effects have been established for Genferon Light spray.Use during pregnancy and breastfeeding
Spray Genferon Light can be used by pregnant women and nursing mothers without restrictions, according to usual dosages. Suppositories Genferon Light. Today, the safety of using Genferon Light suppositories has been proven during pregnancy from 13 to 40 weeks, that is, the II and III trimesters of gestation. The effects on the woman’s body and fetus during pregnancy from 1 to 12 weeks have not been clarified. Experimental studies on animals revealed the safety of Genferon Light in relation to the fetus, but also a moderate increase in the risk of miscarriage in women.
Genferon Light does not pass into breast milk, but causes activation of immune processes in a woman’s body, including the formation of antibodies against pathogenic microbes. Antibodies freely penetrate into mother's milk. During treatment of a nursing mother with Genferon Light, the child may suffer from aggressive antibodies and suppressed pathogenic microbes entering his body with breast milk. Therefore, it is recommended to stop breastfeeding for the entire period of treatment.
Pregnant women between 28 and 34 weeks can use Genferon Light for the treatment of infectious and inflammatory diseases, 1 suppository 125,000 IU twice a day. Suppositories are administered every other day. The full course of therapy is 5 days, then a break for another 5 days. Such 5-day courses are repeated a maximum of 7 times.
Pregnant women at 35–40 weeks can use Genferon Light 250,000 suppositories to treat infectious and inflammatory pathologies. Administer 1 suppository twice a day every day for at least 5 days. After which they take a break for 5 days and repeat the course of treatment a maximum of 7 more times.
The number of 5-day courses of treatment for pregnant women is determined taking into account the improvements achieved and the normalization of test results.
The second option for treating inflammation of the urinary system in pregnant women is the following: 1 suppository of 250,000 IU, or 125,000 IU twice a day for 10 days.
Trade name
GENFERON® LIGHT
International nonproprietary name
Dosage form
Suppositories 125,000 IU, 250,000 IU for vaginal or rectal administration
Compound
One suppository contains
active substances:
excipients: dextran 60,000, macrogol 1500, polysorbate 80, T2 emulsifier, sodium hydrogen citrate, citric acid, purified water, hard fat.
Description
Suppositories are white or white with a yellowish tint, cylindrical in shape with a pointed end, uniform in longitudinal section. An air rod or funnel-shaped depression is allowed on the cut.
Pharmacotherapeutic group
Immunomodulators. Immunostimulants
ATX code L03A
Pharmacological properties
Pharmacokinetics
When the drug is administered rectally, high bioavailability (more than 80%) of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved. When used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect, due to the low absorption capacity of the vaginal mucosa, is insignificant.
The maximum concentration of interferon in the blood serum is achieved 5 hours after rectal or vaginal administration of the drug. The main route of excretion of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
Pharmacodynamics
GENFERON® LIGHT is a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects.
The composition of the drug GENFERON® LIGHT includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods.
Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.
Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug.
Indications for use
as a component of complex therapy - for the treatment of acute respiratory viral infections and other infectious diseases of bacterial and viral etiology in children
for the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women, against the background of specific therapy prescribed and supervised by a doctor
Directions for use and doses
The drug can be used in adults both vaginally and rectally:
in children - only rectally!
The method of administration, dosage and duration of the course depend on age, the specific clinical situation and are determined by the attending physician.
In adults and children over 7 years of age, GENFERON® LIGHT is used in a dosage of 250,000 IU. In children from birth to 7 years of age, it is safe to use the drug at a dosage of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dosage of 250,000 IU of interferon alfa-2b per suppository.
Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
Chronic infectious and inflammatory diseases of viral etiology in children: 1 suppository (250,000 IU) rectally 2 times a day at 12-hour intervals parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
Side effects
The drug is well tolerated by patients.
Very rare (incidence less than 1 in 10,000 cases)
- allergic reactions (single reports).
These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor.
To date, no severe or life-threatening side effects have been observed.
Contraindications
- individual intolerance to interferon and other substances included in the drug
Drug interactions
GENFERON® LIGHT is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect.
Special instructions
Use with caution during exacerbation of allergic and autoimmune diseases.
Pregnancy and lactation
Clinical studies have proven the effectiveness and safety of using the drug GENFERON® LITE in women who are 13-40 weeks pregnant. The safety of the drug in the 1st trimester of pregnancy has not been studied.
There are no restrictions for use during lactation.
Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms
The drug GENFERON® LIGHT does not affect the performance of potentially hazardous activities that require special attention and speed of reactions.
Overdose
No cases of overdose with GENFERON® LITE have been reported. If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
